about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Eli Lil­ly strips oust­ed CFO Josh Smi­ley of $24M in pay af­ter 'i­nap­pro­pri­ate mes­sages' scan­dal

5 years ago
People

Dyno sketch­es tens of thou­sands of vi­able next-gen AAV cap­sids with the help of ma­chine learn­ing — pa­per

5 years ago
AI
Cell/Gene Tx

No­var­tis' San­doz splurges on a trio of GSK an­tibi­otics, dou­bling down with a $500M bet on a field strug­gling to ...

5 years ago
Deals

As­traZeneca looks to re­bound from pro­duc­tion de­lays for its Covid-19 vac­cine with new fill-fin­ish deal

5 years ago
Outsourcing
Coronavirus

Ab­b­Vie taps Jen­nifer Doud­na start­up for li­cens­ing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edit­ed CAR-Ts

5 years ago
Deals
Cell/Gene Tx

On the hunt for a bet­ter an­ti­body, BigHat Bio­sciences de­buts with $19M Se­ries A to scale its 'wet lab' AI plat­form

5 years ago
Financing
AI

Eli Lil­ly ousts CFO Josh Smi­ley af­ter 'i­nap­pro­pri­ate re­la­tion­ship' with em­ploy­ee, ap­points suc­ces­sor in Anat ...

5 years ago
People
Pharma

Lon­za of­floads spe­cial­ty in­gre­di­ents unit in $4.7B sale to Bain Cap­i­tal, Cin­ven in con­sol­i­da­tion around bio­phar­ma

5 years ago
Outsourcing
Manufacturing

For­mer Gale­na chief Mark Ahn back in hot wa­ter as DOJ lev­els in­sid­er trad­ing charges for con­sul­tant work

5 years ago
People
Pharma

TG Ther­a­peu­tics scores con­di­tion­al FDA go-ahead for a drug it's pitch­ing as a safer PI3K

5 years ago
FDA+

Bris­tol My­ers Squibb earns long-await­ed FDA nod for liso-cel, join­ing short list of lym­phoma CAR-T win­ners

5 years ago
Pharma
FDA+

FDA blasts Mer­ck­'s bid for ad­ju­vant Keytru­da in TNBC be­fore ad­comm, call­ing late-stage da­ta 'ques­tion­able'

5 years ago
Pharma
FDA+

Re­gen­eron has a win­ner in Dupix­ent and big sales hopes. So why are so few pa­tients tak­ing it?

5 years ago
Pharma

Mer­ck CEO Ken Fra­zier pre­pares to step down af­ter 29 years, hand­ing the keys to the Keytru­da race car to CFO Robert ...

5 years ago
People

#WCLC21: Mer­ck pokes Bris­tol My­ers in the eye with Keytru­da da­ta show­ing safe­ty red flags in Yer­voy com­bo tri­al

5 years ago
Pharma

#WCLC21: As­traZeneca's EGFR in­hibitor Tagris­so cuts re­lapse, death risks in pa­tients with and with­out pri­or ...

5 years ago
Pharma

WCLC: As­traZeneca builds case for grow­ing ADC pipeline with dou­ble wins in ad­vanced lung can­cer

5 years ago
R&D

Take­da earns win for its TKI in­hibitor in tiny lung can­cer group — but GI side ef­fects could be an ear­ly red flag

5 years ago
R&D

Af­ter sting­ing FDA set­back, Glax­o­SmithK­line's Vi­iV fi­nal­ly notch­es US ap­proval for long-act­ing HIV in­jec­tion

5 years ago
FDA+

BIO looks to re­struc­ture, lay­ing off staff amid chal­lenge to the trade org's nor­mal face-to-face style

5 years ago
Pharma

News brief­ing: Ve­rastem CMO ex­its two weeks af­ter join­ing com­pa­ny; Ther­mo Fish­er inks $550M M&A deal

5 years ago
News Briefing

Bris­tol My­ers Squibb gets re­view date for Op­di­vo com­bo in gas­tric can­cer, look­ing to over­turn Keytru­da's 3-year lead

5 years ago
FDA+

As­traZeneca keeps the ball rolling on Dai­ichi-part­nered En­her­tu, pick­ing up 2nd in­di­ca­tion in gas­tric can­cer

5 years ago
Pharma
FDA+

Eli Lil­ly tees up dis­cov­ery pact worth more than $1.6B with Merus for T cell-fo­cused bis­pe­cif­ic an­ti­bod­ies

5 years ago
Deals
Discovery
First page Previous page 16171819202122 Next page Last page
A service from the Financial Times